SM-17

N/A

Report date: 2026/04/07 20:00:20
First In Class

Base Information

Drug NameSM-17
Drug Alias NameSM-17SM17
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-17 receptor B inhibitors
TargetsInterleukin-17 receptor B
Therapy Area/IndicationsDermatitis, AtopicIdiopathic Pulmonary FibrosisAsthma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSinomab Bioscience Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSinomab Bioscience LtdSinolink Pharma (Suzhou) Ltd
Inactive CompaniesN/A
Active IndicationsDermatitis, AtopicIdiopathic Pulmonary FibrosisAsthma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A